Outsourcing: Analysis and developments of contract service providers to the pharmaceutical and biotechnology industries - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Outsourcing
Contract manufacturing organizations (CMOs) and contract research organizations (CROs). Global sourcing of pharma ingredients and services. Trends and challenges for the biopharmaceutical and pharmaceutical industries.

Acute Need for Supply Chain Transparency

August 4, 2014

PTSM: Pharmaceutical Technology Sourcing and Management

Biopharma manufacturers must reduce the risk in their complex supply chains

Relationship-building at Top of Mind for Clients

August 2, 2014

Pharmaceutical Technology

Annual study shows CMO technical expertise is not enough.

Pharma Investments Reflect Key Industry Trends

August 2, 2014

Pharmaceutical Technology

Shrinking facility size, growth of biologics, and emerging market demand influence pharma investments.

Solid-Dosage Forms Demand Traditional and Emerging Technologies

August 1, 2014
Pharmaceutical Technology

Contract development and manufacturing organizations identify trends, challenges, and emerging technology and service needs for solid and semi-solid dosage forms.

Outsourcing Grows in Europe

August 1, 2014

Pharmaceutical Technology Europe

Eric Langer of BioPlan Associates describes the development of biopharmaceutical outsourcing in Europe over the past 25 years.

Technologies Key for Biologics to Meet Expectations

August 1, 2014
Pharmaceutical Technology

Representatives of contract service organizations that develop biologic-based drugs discussed technology trends such as high-throughput screening and single-use systems.

Quality by Design in Contract Service Relationships

August 1, 2014
Pharmaceutical Technology

Contract service providers describe how quality by design has influenced a drug sponsor's expectations of suppliers.

Europe's Need for Early Development Pharmaceutical Manufacturing Expertise

August 1, 2014

Pharmaceutical Technology

Despite the growth of specialist companies with capabilities across various therapeutic areas in Europe, there is still a need for early development expertise with end-to-end pharmaceutical manufacturing capabilities.

Positive Outlook for Outsourcing

August 1, 2014

Pharmaceutical Technology

Contract services ride high as funding floods bio/pharma.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here